SonKRd for newly diagnosed t(11;14) myeloma patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of medicines (SonKRd) for people who have just been diagnosed with multiple myeloma and have a specific genetic change called t(11;14). The goal is to see if this treatment works well before a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have just been diagnosed with multiple myeloma and have not yet started treatment
- A special test (FISH) shows your myeloma cells have a change called t(11;14)
- You are generally well enough to consider a stem cell transplant in the future
- Your kidney, liver, and blood counts are in a certain range (your doctor will check)
- You are not pregnant or breastfeeding, and you agree to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins on myeloma cells (BCMA and GPRC5D). It is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.